Nonsquamous† histology3 and ALIMTA
Learn about how histology predicts which
See histology data
patients are most likely to gain a survival benefit
with ALIMTA® (pemetrexed for injection), and see
the prevalence of nonsquamous histology in
patients with NSCLC in the United States.
‡ The subgroup of “Other” represents patients with a primary diagnosis of NSCLC whose
disease did not clearly qualify as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.